Log in

NASDAQ:CADX - Cadence Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cadence Pharmaceuticals, Inc (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:CADX
CUSIP12738T10
Phone+1-858-4361400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CADX News and Ratings via Email

Sign-up to receive the latest news and ratings for CADX and its competitors with MarketBeat's FREE daily newsletter.


Cadence Pharmaceuticals (NASDAQ:CADX) Frequently Asked Questions

What is Cadence Pharmaceuticals' stock symbol?

Cadence Pharmaceuticals trades on the NASDAQ under the ticker symbol "CADX."

Has Cadence Pharmaceuticals been receiving favorable news coverage?

Media headlines about CADX stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cadence Pharmaceuticals earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Cadence Pharmaceuticals.

Who are some of Cadence Pharmaceuticals' key competitors?

What other stocks do shareholders of Cadence Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cadence Pharmaceuticals investors own include NovaBay Pharmaceuticals (NBY), Plus500 (PLUS), National Grid (NG), Lookers (LOOK), Hardy Oil & Gas (HDY), Greene King (GNK), Mortgage Choice (MOC), Cimic Group (CIM), Charter Hall Group (CHC) and Randstad (RAND).

What is Cadence Pharmaceuticals' official website?

The official website for Cadence Pharmaceuticals is http://www.cadencepharm.com/.

How can I contact Cadence Pharmaceuticals?

Cadence Pharmaceuticals' mailing address is 12481 High Bluff Dr Ste 200, SAN DIEGO, CA 92130-3583, United States. The biopharmaceutical company can be reached via phone at +1-858-4361400.


MarketBeat Community Rating for Cadence Pharmaceuticals (NASDAQ CADX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  183 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Cadence Pharmaceuticals and other stocks. Vote "Outperform" if you believe CADX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CADX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel